title: Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study.
abstract: Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.
authors.affiliation: Ohio State University Health Center, Columbus.
authors.forename: E H
authors.initials: EH
authors.lastname: Kraut
authors.forename: T
authors.initials: T
authors.lastname: Fleming
authors.forename: M
authors.initials: M
authors.lastname: Segal
authors.forename: J A
authors.initials: JA
authors.lastname: Neidhart
authors.forename: B C
authors.initials: BC
authors.lastname: Behrens
authors.forename: J
authors.initials: J
authors.lastname: MacDonald
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D006690:Bisbenzimidazole / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
chemical_list: D006690:Bisbenzimidazole